Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Jazz Pharmaceuticals JAZZ in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 6 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 5 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $181.11, a high estimate of $207.00, and a low estimate of $162.00. This current average has increased by 2.84% from the previous average price target of $176.11.
Decoding Analyst Ratings: A Detailed Look
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mohit Bansal | Wells Fargo | Raises | Overweight | $170.00 | $130.00 |
| David Amsellem | Piper Sandler | Maintains | Overweight | $163.00 | $163.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $179.00 | $179.00 |
| Ami Fadia | Needham | Maintains | Buy | $207.00 | $207.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $179.00 | $179.00 |
| Oren Livnat | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $207.00 | $207.00 |
| David Amsellem | Piper Sandler | Lowers | Overweight | $163.00 | $166.00 |
| Joel Beatty | Baird | Raises | Outperform | $162.00 | $154.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Jazz Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Jazz Pharmaceuticals analyst ratings.
Get to Know Jazz Pharmaceuticals Better
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Insights: Jazz Pharmaceuticals
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.52%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.39%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 5.42%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.82%, the company showcases efficient use of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 1.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
